| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0885-3924(00)00194-9 |
| P698 | PubMed publication ID | 11027905 |
| P2093 | author name string | Casuccio A | |
| Mercadante S | |||
| Arcuri E | |||
| Tirelli W | |||
| P2860 | cites work | Cancer pain: management | Q35253547 |
| Cognitive failure in patients with terminal cancer: a prospective study | Q35791467 | ||
| Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain | Q39471654 | ||
| Ketamine as an adjunct to morphine in the treatment of pain | Q39474121 | ||
| Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design | Q39481296 | ||
| Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence | Q40485751 | ||
| The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions | Q41138419 | ||
| Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. | Q41652154 | ||
| Paradoxical pain | Q42562338 | ||
| Predictive factors and opioid responsiveness in cancer pain | Q43070777 | ||
| Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient | Q44333045 | ||
| The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. | Q45085647 | ||
| Effects of intravenous ketamine on gastrointestinal motility in the dog | Q51600391 | ||
| Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. | Q51611375 | ||
| Evidence of a role for N-methyl-D-aspartate (NMDA) receptors in the facilitation of tail withdrawal after spinal transection. | Q51635381 | ||
| Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. | Q51644389 | ||
| Continuous subcutaneous injection of ketamine for cancer pain. | Q51737018 | ||
| Organic hallucinosis in patients receiving high doses of opiates for cancer pain | Q52045363 | ||
| Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction | Q95815497 | ||
| P433 | issue | 4 | |
| P921 | main subject | morphine | Q81225 |
| P304 | page(s) | 246-252 | |
| P577 | publication date | 2000-10-01 | |
| P1433 | published in | Journal of Pain and Symptom Management | Q6295708 |
| P1476 | title | Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study | |
| P478 | volume | 20 |
| Q43195003 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain |
| Q92405480 | A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study |
| Q34874438 | Adjuvant ketamine analgesia for the management of cancer pain |
| Q74594833 | Advances in cancer pain management |
| Q45961975 | An observational study on the effect of S+-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. |
| Q44105800 | Analgesia with ketamine in a patient with perioperative opioid tolerance |
| Q38741766 | Assessment of low-dose i.v. ketamine infusions for adjunctive analgesia |
| Q38029585 | Can gradual dose titration of ketamine for management of neuropathic pain prevent psychotomimetic effects in patients with advanced cancer? |
| Q39202806 | Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain |
| Q38124029 | Clinical guideline for pharmacological management of cancer pain: the Japanese Society of Palliative Medicine recommendations. |
| Q37790054 | Combination drug therapy for chronic pain: a call for more clinical studies |
| Q24202050 | Combination pharmacotherapy for the treatment of neuropathic pain in adults |
| Q55535831 | Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. |
| Q37523991 | Current approaches with the glutamatergic system as targets in the treatment of neuropathic pain |
| Q34779398 | Current aproach to cancer pain management: Availability and implications of different treatment options. |
| Q37029155 | Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial |
| Q34515209 | Drug interactions with patient-controlled analgesia |
| Q44343291 | Effects of NMDA receptor antagonists on acute μ-opioid analgesia in the rat |
| Q39229035 | Effects of low-dose IV ketamine on peripheral and central pain from major limb injuries sustained in combat |
| Q39198876 | Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients |
| Q36066043 | Emerging analgesics in cancer pain management |
| Q34539972 | Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care |
| Q30981259 | Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review |
| Q24197473 | Ketamine as an adjuvant to opioids for cancer pain |
| Q24250218 | Ketamine as an adjuvant to opioids for cancer pain |
| Q38705422 | Ketamine as an adjuvant to opioids for cancer pain. |
| Q27007770 | Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature |
| Q90388259 | Ketamine for pain management |
| Q35020147 | Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases |
| Q57211059 | Ketamine infusion therapy for chronic pain management in South Korea: A national survey for pain physicians with a narrative review |
| Q58740675 | Ketamine reduces aversion in rodent pain models by suppressing hyperactivity of the anterior cingulate cortex |
| Q44596217 | Ketamine to Control Pain |
| Q28077524 | Ketamine: 50 Years of Modulating the Mind |
| Q52553682 | Ketamine: miracle drug or latest fad? |
| Q43121042 | Long-Term Intravenous Ketamine for Analgesia in a Child with Severe Chronic Intestinal Graft versus Host Disease |
| Q37154731 | Management of breakthrough pain in patients with cancer. |
| Q37998511 | Management of pain in the elderly at the end of life |
| Q93169991 | Mitogen-activated protein kinase signaling mediates opioid-induced presynaptic NMDA receptor activation and analgesic tolerance |
| Q90230479 | Molecular Basis of Cancer Pain Management: An Updated Review |
| Q35044033 | N-methyl-D-aspartate- enhanced analgesia |
| Q35627408 | Opioid effectiveness and side effects in chronic pain |
| Q34225077 | Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness |
| Q35044015 | Opioids: a review |
| Q37237499 | Oral ketamine for children with chronic pain: a pilot phase 1 study |
| Q39227024 | Oral ketamine for sickle cell crisis pain refractory to opioids |
| Q35059783 | Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care |
| Q34554563 | Oral ketamine in the palliative care setting: a review of the literature and case report of a patient with neurofibromatosis type 1 and glomus tumor-associated complex regional pain syndrome |
| Q35163526 | Pain in terminally ill patients: guidelines for pharmacological management |
| Q38672359 | Pharmacological Management of Cancer-Related Pain |
| Q38840224 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review |
| Q38370071 | Pharmacological options for the management of refractory cancer pain-what is the evidence? |
| Q37907386 | Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature |
| Q37915538 | Pharmacological treatment of opioid-induced hyperalgesia: a review of the evidence |
| Q35095194 | Pharmacotherapy of cancer-related episodic pain |
| Q35729129 | Postoperative pain assessment tools in day surgery: literature review |
| Q44347860 | Prospective audit of short-term concurrent ketamine, opioid and anti-inflammatory ('triple-agent') therapy for episodes of acute on chronic pain. |
| Q34734247 | Recent progress in the pharmacotherapy of cancer pain |
| Q39143423 | Role of Ketamine and Methadone as Adjunctive Therapy in Complex Pain Management: A Case Report and Literature Review |
| Q39382236 | Sleep disorders in advanced cancer patients: prevalence and factors associated |
| Q48255167 | Successful reversal of hyperalgesia/myoclonus complex with low-dose ketamine infusion |
| Q35041376 | Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain |
| Q44340503 | The importance of opioid tolerance: a therapeutic paradox |
| Q56452284 | The management of neuropathic pain in cancer |
| Q36854479 | The rationale for a multimodal approach in the management of breakthrough cancer pain: a review |
| Q26770796 | The role of ketamine in the treatment of chronic cancer pain |
| Q34182127 | The use of ketamine in complex regional pain syndrome: possible mechanisms |
| Q79430529 | Update on adjuvant medications for chronic nonmalignant pain |
| Q33514190 | Use of oral ketamine in chronic pain management: a review. |
| Q38647566 | ZL006, a small molecule inhibitor of PSD-95/nNOS interaction, does not induce antidepressant-like effects in two genetically predisposed rat models of depression and control animals. |
| Q79866760 | [Intravenous S-+-ketamine for treatment of visceral pain in the final phase] |
Search more.